TABLE C-1 Mercury Content from Thimerosal in the Routinely Recommended Pediatric Vaccines1 in the United States, April 2004

Vaccine

Brand Name

Manufacturer

Hg [μg/dose]

DTaP

(Diphtheria and tetanus toxoids and acellular pertussis)

Tripedia

Aventis Pasteur, Inc.

≤0.3

Infanrix

Glaxo-SmithKline

0

Daptacel

Aventis Pasteur, Ltd

0

Td1

(Tetanus and diphtheria toxoids)

None

Aventis Pasteur, Inc.

25

Decavac

Aventis Pasteur, Inc.

= 0.3

None

Aventis Pasteur, Ltd

0

None

Mass Public Health

8.3

DTaP-Hib

(Diphtheria and tetanus toxoids with acellular pertussis combined with Haemophilus influenzae type b)

TriHIBit2

Aventis Pasteur

≤0.3

Hib

(Haemophilus influenzae type b)

ActHIB/OmniHib

Aventis Pasteur, SA

0

HibTITER (Single dose)

Wyeth-Lederle

0

PedvaxHIB liquid

Merck

0

Hib/HepB (Haemophilus influenzae type b combined with Hepatitis B )

COMVAX

Merck

0

Hep B

(Hepatitis B)

(pediatric formulation)

Engerix B

Glaxo-SmithKline

<0.5

Recombivax HB

Merck

0

Influenza

Fluzone3

Aventis Pasteur, Inc.

12.5

Fluzone

Aventis Pasteur, Inc.

≤0.5ug/

(Preservative Free)

 

0.25mL dose

Pneumococcal

Prevnar

(pneumoconjugate)

Wyeth

0

IPV

(Inactivated polio vaccine)

IPOL

Aventis Pasteur, SA

0

Poliovax

Aventis Pasteur, Ltd.

0

MMR

(Measles, mumps, and rubella)

MMR-II

Merck

0

Varicella

Varivax

Merck

0

1Licensed for persons 7 years of age and older.

2For use in children 15 to 18 months of age.

3Influenza vaccine is recommended for children 6-23 months of age. MMWR (2004) 52:1-4; MMWR (2004) 53:1-3.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement